(Q35576853)

English

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study

scientific article published on March 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

phase II clinical trial

0 references

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

David R Gandara

9

object named as

David R Gandara

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

author name string

Primo N Lara

1

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Christopher P Evans

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

David I Quinn

4

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Przemyslaw Twardowski

5

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Gurkamal Chatta

6

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Edwin Posadas

7

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Walter Stadler

8

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

publication date

1 March 2009

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Anti-Cancer Drugs

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

179-184

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Nonreceptor tyrosine kinases in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Neuropeptides as growth factors. Possible roles in human diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Serotonin as a growth factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

12 July 2018

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3225398

26 September 2018

Clinical states in prostate cancer: toward a dynamic model of disease progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/19396016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bombesin and the C-terminal tetradecapeptide of gastrin-releasing peptide are growth factors for normal human bronchial epithelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19396016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands

1 reference

https://pubmed.ncbi.nlm.nih.gov/19396016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevated Plasma Chromogranin-A Concentrations in Prostatic Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19396016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19396016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/CAD.0B013E328325A867

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35576853&oldid=1580139168"